

IDS #2
3/9/02

"Express Mail" mailing label number EL018700462US
Date of Deposit Dec 1, 2003

Date of deposit Jan. 25, 1982
I hereby certify that this paper or fee is

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. 1.10 on the date indicated above and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Dever Thomas
Printed Name

Printed Name

Deeex) Thomas)
Signature

Signature

1046 U.S. PRO

01/33/03

PATENT APPLICATION
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Chin-Ming Chang and
Henry A. Havel

For : STABILIZED TERIPARATIDE
SOLUTIONS

Docket No. : X-10911A

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

As a means of complying with the duty of disclosure, Applicant submit an "Information Disclosure Citation In An Application" on a modified Form PTO-1449 for consideration by the Examiner.

As permitted by 37 C.F.R. 1.98(d), Applicants refer to parent application Serial No. 09/555,476, filed May 31, 2000, for copies of the listed references.

Since this Statement is being filed in accordance with 37 C.F.R. 1.97(b), Applicant submit that no additional fee is required.

Applicant request consideration of this information.

Respectfully submitted,

Thru D. A. H.

Thomas D. Webster
Attorney for Applicants
Registration No. 39,872
Phone: 317-276-9934

Eli Lilly and Company
Patent Division/TDW
Lilly Corporate Center
Indianapolis, IN 46285

FORM PTO 1449 (modified)		Atty. Docket No. X-10911A	Serial No
INFORMATION DISCLOSURE CITATION IN AN APPLICATION		Applicants Chang, et al.	
		Filing Date	Group

11046 U.S. PTO
10/05509
D1/23/02

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Sub-class	Filing Date If Appropriate
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Sub-class	Translation	
							yes	no
	BA	WO 99/5353	04/28/98	PCT				
	BB	WO 95/17207	06/29/95	PCT				
	BC	EP O 619 119 A1	10/12/94	EPO				
	BD	WO 91/06564	05/16/91	PCT				
	BE	EP O 302 772 A1	02/08/89	EPO				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	CA	Reeve et al., "Anabolic effect of human parathyroid hormone fragment on trabecular bone in involutional osteoporosis: a multicentre trial", Br. Med. J., 280(6228):1340-1344, 1980
	CB	Reeve et al., "ANABOLIC EFFECT OF LOW DOSES OF A FRAGMENT OF HUMAN PARATHYROID HORMONE ON THE SKELETON IN POSTMENOPAUSAL OSTEOPOROSIS", The Lancet, 1:1035-1038, 1976
	CC	Reeve et al., "Preliminary Trial of Low Doses of Human Parathyroid Hormone 1-34 Peptide in Treatment of Osteoporosis", Calcif. Tissue Res., 21:469-477, 1976

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

FORM PTO 1449 (modified)			Atty. Docket No. X-10911A	Serial No
INFORMATION DISCLOSURE CITATION IN AN APPLICATION			Applicant Chang et al.	
			Filing Date	Group
	CD		Hodsman et al., "Biochemical responses to sequential human parathyroid hormone (1-38) and calcitonin in osteoporotic patients", Bone and Mineral, 9(2):137-152, 1990	
	CE		Tsai et al., "Bone Responsiveness to Parathyroid Hormone in Normal and Osteoporotic Postmenopausal Women", J. Clin. Endocrinol Metab., 169(5):1024-1027, 1989	
	CF		Isaac et al., "Absence of Effect of 1-34 h PTH on Plasma TSH, GH, FSH, LH, ACTH and Cortisol in Normal Man", Horm. Metab. Res., 12(9):487-488, 1980	
	CG		Law et al., "Rapid Development of Renal Resistance to Low Doses of Synthetic Bovine Parathyroid Hormone Fragment 1-34", J. Clin Invest., 72(3):1106-1113, 1983	
	CH		Hulter et al., "Chronic Continuous PTH Infusion Results in Hypertension in Normal Subjects", J. Clin Hypertens, 2(4):360-370, 1986	
	CI		Hodsman et al., "Bone densitometric and histomorphometric responses to sequential human parathyroid hormone (1-38) and salmon calcitonin in osteoporotic patients", 14(1):67-83, 1991	
	CJ		Martindale, The Extra Pharmacopoeia, The Pharmaceutical Press, London, 29th Edition, 1989 p. 1338 (Copy not provided)	
	CK			
	CL			
	CM			
	CN			
	CO			
	CP			
	CQ			
	CR			
EXAMINER			DATE CONSIDERED	
<small>*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.</small>				

11046 USPTO
10/05/99
01/23/02